Product

LGM2605

Unmet Medical Needs


Low Th2 Asthma

There is no effective treatment to mitigate low Th2 asthma, for which there are 175,000 patients in the U.S.

Lung Transplants

There is a need to rehabilitate and improve lung function and preserve donor lungs ex-vivo to increase the supply of viable lungs and improve outcomes for transplantation for individuals with end stage lung disease

Pulmonary Fibrosis

Pulmonary Fibrosis is a progressive deadly disease that kills 40,000 people annually
50,000 new cases diagnosed per year, median survival is 3-5 years
Many patients go on to require a lung transplant, which has poor survival rates
There is a clear need for new therapies to treat Pulmonary Fibrosis


Solution: LGM2605 – novel small molecule


LGM2605 is intended for use:

  • As an oral treatment for low Th2 asthma
  • To salvage donor lung organs that are currently not suitable for lung transplant
  • To improve donor lung storage conditions and extend the donor lung preservation period
  • As an oral treatment for Pulmonary Fibrosis
    • Control and in some cases reverse progression of the disease
    • Improve Pulmonary Fibrosis patient mobility/quality of life
    • Use alone or in combination with existing therapies
Other opportunities:
  • Supportive care to prevent lung damage during radiation treatment of thoracic cancers
  • Mitigation agent to treat radiation lung damage from nuclear accident or attack
    (Contract awarded by NIAID to support development activities required for FDA approval under the Animal Rule. If the development program is successful, LGM2605 will be a candidate for procurement for the U.S. Strategic National Stockpile.)